Madrigal Pharmaceuticals, Inc. (MDGL) Financials

MDGL Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 640.5 million 235.2 million
2023-09-30 238.0 million 215.7 million
2023-06-30 302.5 million 199.0 million
2023-03-31 332.4 million 182.3 million

MDGL Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -81.0 million 14.9 million
2023-09-30 -85.3 million 12.7 million
2023-06-30 -75.4 million 11.0 million
2023-03-31 -84.1 million 11.3 million

MDGL Net Income

No data available :(

MDGL Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 634.1 million - 1.7 million
2023-09-30 232.4 million - 1.8 million
2023-06-30 298.4 million - 411000
2023-03-31 329.5 million 84.0 million 653000

MDGL Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 19.8 million
2023-09-30 18.5 million
2023-06-30 18.3 million
2023-03-31 18.2 million

MDGL Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 1.0 million 70.5 million 46.5 million -
2023-09-30 339000 71.0 million 27.6 million -
2023-06-30 69000 68.6 million 17.8 million -
2023-03-31 35000 62.2 million 16.2 million -

MDGL Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 - 142000
2023-09-30 - 135000
2023-06-30 - 126000
2023-03-31 - 124000

MDGL

Price: $229.84

52 week price:
119.76
322.67

Earnings Per Share: -19.99 USD

P/E Ratio: -8.90

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 132314

Ebitda: -8.4 million

Market Capitalization: 5.0 billion

Links: